News Release

 View printer-friendly version

Charles River Laboratories Announces Second-Quarter 2022 Results

– Second-Quarter Revenue of $973.1 Million

– Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77

– Reduces 2022 Guidance –

WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 3, 2022-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2022. For the quarter, revenue was $973.1 million, an increase of 6.4% from $914.6 million in the second quarter of 2021.

Acquisitions contributed 2.3% to consolidated second-quarter revenue growth. The divestitures of the Research Models and Services operations in Japan (RMS Japan) and CDMO site in Sweden (CDMO Sweden) in October 2021 reduced reported revenue growth by 2.0%. The impact of foreign currency translation reduced reported revenue growth by 3.4%. Excluding the effect of these items, organic revenue growth of 9.5% was driven primarily by the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) business segments.

On a GAAP basis, second-quarter net income attributable to common shareholders was $109.3 million, an increase of 23.6% from net income of $88.4 million for the same period in 2021. Second-quarter diluted earnings per share on a GAAP basis were $2.13, an increase of 23.8% from $1.72 for the second quarter of 2021. The increases in GAAP net income and earnings per share were primarily driven by higher revenue and acquisition-related adjustments. In addition, GAAP net income and earnings per share included a loss from the Company’s venture capital and other strategic investments of $0.14 per share in the second quarter of 2022, compared to a gain of $0.14 per share for the same period in 2021. The Company’s venture capital and other strategic investment performance has been excluded from non-GAAP results.

On a non-GAAP basis, net income was $141.9 million for the second quarter of 2022, an increase of 6.0% from $133.8 million for the same period in 2021. Second‑quarter diluted earnings per share on a non-GAAP basis were $2.77, an increase of 6.1% from $2.61 per share for the second quarter of 2021. The non-GAAP net income and earnings per share increases were driven primarily by higher revenue and operating margin improvement, partially offset by higher interest expense and tax rate.

James C. Foster, Chairman, President and Chief Executive Officer, said, “Our second-quarter financial results reflect the sustained trends that continue to support our business, particularly our DSA and RMS business segments for which demand continues to be strong and the performance remains consistent with our initial outlook for the year. Safety Assessment continues to benefit from a growing backlog that is well above the prior-year level and solid booking activity, which support the anticipated DSA growth acceleration in the second half of the year.”

“However, these robust trends were offset by headwinds from our CDMO business, as well as unfavorable changes in foreign exchange and interest rates, which have significantly intensified over the past two months. We have revised our financial outlook for 2022 to account for these escalating headwinds, resulting in lower revenue growth and earnings per share guidance for the year,” Mr. Foster concluded.

 

Second-Quarter Segment Results

Research Models and Services (RMS)

Revenue for the RMS segment was $186.4 million in the second quarter of 2022, an increase of 5.5% from $176.7 million in the second quarter of 2021. Organic revenue growth of 8.5% was primarily driven by research model services, particularly the Insourcing Solutions (IS) and Genetically Engineered Models and Services (GEMS) business. Revenue growth for research models in North America and China also contributed. Revenue in China increased in the second quarter, but was negatively impacted by COVID-related restrictions that affected client order activity.

In the second quarter of 2022, the RMS segment’s GAAP operating margin decreased to 21.2% from 24.1% in the second quarter of 2021, and on a non-GAAP basis, the operating margin decreased to 24.9% from 27.4%. The GAAP and non-GAAP operating margin decreases were driven primarily by the COVID-related revenue impact in China.

Discovery and Safety Assessment (DSA)

Revenue for the DSA segment was $591.9 million in the second quarter of 2022, an increase of 9.6% from $540.1 million in the second quarter of 2021. Organic revenue growth of 12.9% was driven by strong demand and price increases in the Safety Assessment and Discovery Services businesses.

In the second quarter of 2022, the DSA segment’s GAAP operating margin increased to 21.8% from 19.4% in the second quarter of 2021, and on a non-GAAP basis, the operating margin increased to 25.3% from 23.5%. The GAAP and non-GAAP operating margin increases were driven primarily by operating leverage from higher revenue in both the Discovery Services and Safety Assessment businesses.

Manufacturing Solutions (Manufacturing)

Revenue for the Manufacturing segment was $194.8 million in the second quarter of 2022, a decrease of 1.5% from $197.8 million in the second quarter of 2021. Organic revenue growth of 1.0% reflected higher revenue in the Biologics Testing and Microbial Solutions businesses, which was effectively offset by a revenue decline in the CDMO business.

In the second quarter of 2022, the Manufacturing segment’s GAAP operating margin increased to 32.1% from 28.7% in the second quarter of 2021. The GAAP operating margin in the second quarter benefitted from acquisition-related adjustments associated with last year’s Cognate and Vigene CDMO transactions. On a non-GAAP basis, the operating margin decreased to 28.6% from 33.2% in the second quarter of 2021, primarily as a result of the CDMO business.

 

Reduces 2022 Guidance

The Company is reducing its 2022 financial guidance, due primarily to headwinds associated with the CDMO business, foreign exchange due to the strengthening U.S. dollar, and interest expense due to the rising interest rate environment.

Reported revenue growth guidance is being reduced by 450 basis points to reflect unfavorable movements in foreign currency translation, as well as a lower revenue growth rate in the Manufacturing segment, driven principally by the CDMO business.

Organic revenue growth guidance for 2022 is being reduced by 250 basis points, also driven largely by the CDMO business. The Company continues to expect the organic revenue growth rates for the DSA and RMS segments will be in line with the initial outlooks for the year.

The Company is also reducing GAAP and non-GAAP earnings per share guidance primarily to reflect the headwinds from the CDMO business and foreign exchange, as well as higher interest expense. These factors will be partially offset by discretionary cost controls.

The Company’s updated guidance for revenue growth, earnings per share, and cash flow is as follows:

2022 GUIDANCE

CURRENT

PRIOR

Revenue growth, reported

9.0% – 11.0%

13.5% – 15.5%

Less: Contribution from acquisitions/divestitures, net

~(1.0%)

~(1.0%)

Less: Impact of 53rd week in 2022

~(1.5)%

~(1.5)%

Unfavorable/(favorable) impact of foreign exchange

~3.5%

~1.5%

Revenue growth, organic (1)

10.0% – 12.0%

12.5% – 14.5%

GAAP EPS

$7.90$8.15

$8.70$8.95

Acquisition-related amortization

~$2.20

$2.15$2.25

Acquisition and integration-related adjustments (2)

--

~$0.25

Venture capital and other strategic investment losses/(gains), net (3)

$0.35

$0.20

Other items (4)

~$0.25

~$0.15

Non-GAAP EPS

$10.70$10.95

$11.50$11.75

Cash flow from operating activities

~$700 million

~$810 million

Capital expenditures

~$340 million

~$360 million

Free cash flow

~$360 million

~$450 million

Footnotes to Guidance Table:

(1) Organic revenue growth is defined as reported revenue growth adjusted for completed acquisitions and divestitures, the 53rd week in 2022, and foreign currency translation.
(2) These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration costs, and certain costs associated with acquisition-related efficiency initiatives, offset by adjustments related to contingent consideration and certain indirect tax liabilities.
(3) Venture capital and other strategic investment performance only includes recognized gains or losses. The Company does not forecast the future performance of these investments.
(4) These items primarily relate to charges associated with U.S. and international tax legislation that necessitated changes to the Company’s international financing structure; certain third-party legal costs related to (a) environmental litigation related to the Microbial Solutions business and (b) responses to a U.S. government industry-wide supply chain management inquiry applicable to our Safety Assessment business; and severance and other costs related to the Company’s efficiency initiatives.

 

Webcast

Charles River has scheduled a live webcast on Wednesday, August 3rd, at 9:30 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.

Non-GAAP Reconciliations

The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP free cash flow. Non-GAAP financial measures exclude, but are not limited to, the amortization of intangible assets, and other charges and adjustments related to our acquisitions and divestitures; expenses associated with evaluating and integrating acquisitions and divestitures, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our efficiency initiatives; the impact of the termination of the Company’s pension plans; the write-off of deferred financing costs and fees related to debt financing; investment gains or losses associated with our venture capital and other strategic equity investments; certain legal costs in our Microbial Solutions business related to environmental litigation and in our Safety Assessment business related to producing responses to a U.S. government industry-wide supply chain management inquiry; and adjustments related to the recognition of deferred tax assets expected to be utilized as a result of changes to the our international financing structure and the revaluation of deferred tax liabilities as a result of foreign tax legislation. This press release also refers to our revenue on both a GAAP and non-GAAP basis: “organic revenue growth,” which we define as reported revenue growth adjusted for foreign currency translation, acquisitions, divestitures, and the impact of the 53rd week in 2022. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, the 53rd week in 2022, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.

 

Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the impact of the COVID-19 pandemic; the projected future financial performance of Charles River and our specific businesses; client demand, particularly the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to pricing of our products and services; our expectations with respect to future tax rates and the impact of such tax rates on our business; our expectations with respect to the impact of acquisitions and divestitures completed in 2021 and 2022 on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and spending trends by our clients; and Charles River’s future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, interest rates, enhanced efficiency initiatives, and the assumptions surrounding the COVID-19 pandemic that form the basis for our annual guidance. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the COVID-19 pandemic, its duration, its impact on our business, results of operations, financial condition, liquidity, business practices, operations, suppliers, third party service providers, clients, employees, industry, ability to meet future performance obligations, ability to efficiently implement advisable safety precautions, and internal controls over financial reporting; the COVID-19 pandemic’s impact on client demand, the global economy and financial markets; the ability to successfully integrate businesses we acquire (including Explora BioLabs); the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; disruptions in the global economy caused by the ongoing conflict between the Russian federation and Ukraine; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 16, 2022, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

 
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
               
SCHEDULE 1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands, except for per share data)
               
  Three Months Ended   Six Months Ended
  June 25, 2022   June 26, 2021   June 25, 2022   June 26, 2021
               
Service revenue

$

782,827

 

 

$

715,320

 

 

$

1,503,312

 

 

$

1,341,901

 

Product revenue

 

190,304

 

 

 

199,287

 

 

 

383,748

 

 

 

397,272

 

Total revenue

 

973,131

 

 

 

914,607

 

 

 

1,887,060

 

 

 

1,739,173

 

Costs and expenses:              
Cost of services provided (excluding amortization of intangible assets)

 

522,623

 

 

 

476,762

 

 

 

1,009,487

 

 

 

900,737

 

Cost of products sold (excluding amortization of intangible assets)

 

93,782

 

 

 

95,824

 

 

 

184,029

 

 

 

188,137

 

Selling, general and administrative

 

131,711

 

 

 

171,501

 

 

 

281,744

 

 

 

327,234

 

Amortization of intangible assets

 

37,604

 

 

 

32,970

 

 

 

75,611

 

 

 

61,812

 

Operating income

 

187,411

 

 

 

137,550

 

 

 

336,189

 

 

 

261,253

 

Other income (expense):              
Interest income

 

188

 

 

 

171

 

 

 

315

 

 

 

206

 

Interest expense

 

(3,703

)

 

 

(16,190

)

 

 

(13,137

)

 

 

(45,909

)

Other (expense) income, net

 

(39,783

)

 

 

5,965

 

 

 

(68,408

)

 

 

(21,752

)

Income before income taxes

 

144,113

 

 

 

127,496

 

 

 

254,959

 

 

 

193,798

 

Provision for income taxes

 

33,449

 

 

 

37,580

 

 

 

49,069

 

 

 

39,947

 

Net income

 

110,664

 

 

 

89,916

 

 

 

205,890

 

 

 

153,851

 

Less: Net income attributable to noncontrolling interests

 

1,343

 

 

 

1,468

 

 

 

3,547

 

 

 

3,873

 

Net income attributable to common shareholders

$

109,321

 

 

$

88,448

 

 

$

202,343

 

 

$

149,978

 

               
Earnings per common share              
Net income attributable to common shareholders:              
Basic

$

2.15

 

 

$

1.76

 

 

$

3.99

 

 

$

2.99

 

Diluted

$

2.13

 

 

$

1.72

 

 

$

3.94

 

 

$

2.93

 

               
Weighted-average number of common shares outstanding;              
Basic

 

50,823

 

 

 

50,297

 

 

 

50,732

 

 

 

50,138

 

Diluted

 

51,283

 

 

 

51,334

 

 

 

51,293

 

 

 

51,225

 

                               
 
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
 
 
SCHEDULE 2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except per share amounts)
       
       
  June 25, 2022   December 25, 2021
Assets      
Current assets:      
Cash and cash equivalents

$

200,321

 

 

$

241,214

 

Trade receivables and contract assets, net of allowances for credit losses of $7,928 and $7,180, respectively

 

747,605

 

 

 

642,881

 

Inventories

 

256,765

 

 

 

199,146

 

Prepaid assets

 

80,939

 

 

 

93,543

 

Other current assets

 

107,456

 

 

 

97,311

 

Total current assets

 

1,393,086

 

 

 

1,274,095

 

Property, plant and equipment, net

 

1,383,422

 

 

 

1,291,068

 

Operating lease right-of-use assets, net

 

382,121

 

 

 

292,941

 

Goodwill

 

2,860,258

 

 

 

2,711,881

 

Client relationships, net

 

965,206

 

 

 

981,398

 

Other intangible assets, net

 

67,166

 

 

 

79,794

 

Deferred tax assets

 

42,467

 

 

 

40,226

 

Other assets

 

435,635

 

 

 

352,889

 

Total assets

$

7,529,361

 

 

$

7,024,292

 

       
Liabilities, Redeemable Noncontrolling Interests and Equity      
Current liabilities:      
Current portion of long-term debt and finance leases

$

2,364

 

 

$

2,795

 

Accounts payable

 

211,381

 

 

 

198,130

 

Accrued compensation

 

202,962

 

 

 

246,119

 

Deferred revenue

 

242,084

 

 

 

219,703

 

Accrued liabilities

 

199,234

 

 

 

228,797

 

Other current liabilities

 

190,110

 

 

 

137,641

 

Total current liabilities

 

1,048,135

 

 

 

1,033,185

 

Long-term debt, net and finance leases

 

2,997,221

 

 

 

2,663,564

 

Operating lease right-of-use liabilities

 

365,775

 

 

 

252,972

 

Deferred tax liabilities

 

230,051

 

 

 

239,720

 

Other long-term liabilities

 

195,075

 

 

 

242,859

 

Total liabilities

 

4,836,257

 

 

 

4,432,300

 

Redeemable noncontrolling interests

 

40,177

 

 

 

53,010

 

Equity:      
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding

 

-

 

 

 

-

 

Common stock, $0.01 par value; 120,000 shares authorized; 50,990 shares issued and 50,861 shares outstanding as of June 25, 2022, and 50,480 shares issued and outstanding as of December 25, 2021

 

510

 

 

 

505

 

Additional paid-in capital

 

1,761,125

 

 

 

1,718,304

 

Retained earnings

 

1,183,094

 

 

 

980,751

 

Treasury stock, at cost, 129 and 0 shares, as of June 25, 2022 and December 25, 2021, respectively

 

(38,468

)

 

 

-

 

Accumulated other comprehensive loss

 

(258,555

)

 

 

(164,740

)

Total equity attributable to common shareholders

 

2,647,706

 

 

 

2,534,820

 

Noncontrolling interest

 

5,221

 

 

 

4,162

 

Total equity

 

2,652,927

 

 

 

2,538,982

 

Total liabilities, redeemable noncontrolling interests and equity

$

7,529,361

 

 

$

7,024,292

 

       
 
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
   
SCHEDULE 3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
           
      Six Months Ended
      June 25, 2022   June 26, 2021
  Cash flows relating to operating activities        
  Net income  

$

205,890

 

 

$

153,851

 

  Adjustments to reconcile net income to net cash provided by operating activities:        
  Depreciation and amortization  

 

151,720

 

 

 

129,613

 

  Stock-based compensation  

 

29,549

 

 

 

30,266

 

  Loss on debt extinguishment and other financing costs  

 

1,987

 

 

 

27,980

 

  Deferred income taxes  

 

(14,684

)

 

 

8,891

 

  Loss on venture capital and strategic equity investments, net  

 

23,515

 

 

 

6,910

 

  Contingent consideration, fair value changes  

 

(15,420

)

 

 

-

 

  Other, net  

 

13,520

 

 

 

(475

)

  Changes in assets and liabilities:        
  Trade receivables and contract assets, net  

 

(117,642

)

 

 

(5,224

)

  Inventories  

 

(63,725

)

 

 

(7,107

)

  Accounts payable  

 

31,466

 

 

 

(13,383

)

  Accrued compensation  

 

(38,173

)

 

 

13,932

 

  Deferred revenue  

 

27,641

 

 

 

502

 

  Customer contract deposits  

 

16,100

 

 

 

(2,032

)

  Other assets and liabilities, net  

 

360

 

 

 

13,095

 

  Net cash provided by operating activities  

 

252,104

 

 

 

356,819

 

  Cash flows relating to investing activities        
  Acquisition of businesses and assets, net of cash acquired  

 

(283,392

)

 

 

(1,000,505

)

  Capital expenditures  

 

(163,316

)

 

 

(74,461

)

  Purchases of investments and contributions to venture capital investments  

 

(108,842

)

 

 

(23,266

)

  Proceeds from sale of investments  

 

205

 

 

 

5,204

 

  Other, net  

 

(4,774

)

 

 

839

 

  Net cash used in investing activities  

 

(560,119

)

 

 

(1,092,189

)

  Cash flows relating to financing activities        
  Proceeds from long-term debt and revolving credit facility  

 

2,180,511

 

 

 

4,999,942

 

  Proceeds from exercises of stock options  

 

15,571

 

 

 

35,298

 

  Payments on long-term debt, revolving credit facility, and finance lease obligations  

 

(1,856,262

)

 

 

(4,241,772

)

  Purchase of treasury stock  

 

(38,468

)

 

 

(40,297

)

  Payment of debt extinguishment and financing costs  

 

-

 

 

 

(38,166

)

  Payment of contingent considerations  

 

(10,356

)

 

 

-

 

  Other, net  

 

(32,843

)

 

 

(2,330

)

  Net cash provided by financing activities  

 

258,153

 

 

 

712,675

 

  Effect of exchange rate changes on cash, cash equivalents, and restricted cash  

 

10,756

 

 

 

17,066

 

  Net change in cash, cash equivalents, and restricted cash  

 

(39,106

)

 

 

(5,629

)

  Cash, cash equivalents, and restricted cash, beginning of period  

 

246,314

 

 

 

233,119

 

  Cash, cash equivalents, and restricted cash, end of period  

$

207,208

 

 

$

227,490

 

           
  Supplemental cash flow information:        
  Cash and cash equivalents  

$

200,321

 

 

$

222,969

 

  Restricted cash included in Other current assets  

 

5,797

 

 

 

3,118

 

  Restricted cash included in Other assets  

 

1,090

 

 

 

1,403

 

  Cash, cash equivalents, and restricted cash, end of period  

$

207,208

 

 

$

227,490

 

           
 
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                   
SCHEDULE 4
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1)
(in thousands, except percentages)
                   
      Three Months Ended   Six Months Ended
      June 25, 2022   June 26, 2021   June 25, 2022   June 26, 2021
Research Models and Services                
  Revenue  

$

186,410

 

 

$

176,694

 

 

$

362,952

 

 

$

353,604

 

  Operating income  

 

39,526

 

 

 

42,580

 

 

 

87,408

 

 

 

87,515

 

  Operating income as a % of revenue  

 

21.2

%

 

 

24.1

%

 

 

24.1

%

 

 

24.7

%

  Add back:                
  Amortization related to acquisitions  

 

5,472

 

 

 

5,346

 

 

 

9,310

 

 

 

10,685

 

  Severance  

 

453

 

 

 

-

 

 

 

1,127

 

 

 

7

 

  Acquisition related adjustments (2)  

 

971

 

 

 

520

 

 

 

1,354

 

 

 

976

 

  Total non-GAAP adjustments to operating income  

$

6,896

 

 

$

5,866

 

 

$

11,791

 

 

$

11,668

 

  Operating income, excluding non-GAAP adjustments  

$

46,422

 

 

$

48,446

 

 

$

99,199

 

 

$

99,183

 

  Non-GAAP operating income as a % of revenue  

 

24.9

%

 

 

27.4

%

 

 

27.3

%

 

 

28.0

%

                   
  Depreciation and amortization  

$

13,228

 

 

$

9,844

 

 

$

22,697

 

 

$

19,523

 

  Capital expenditures  

$

13,850

 

 

$

8,512

 

 

$

22,496

 

 

$

11,495

 

                   
Discovery and Safety Assessment                
  Revenue  

$

591,917

 

 

$

540,094

 

 

$

1,136,176

 

 

$

1,041,272

 

  Operating income  

 

128,793

 

 

 

104,514

 

 

 

233,779

 

 

 

195,463

 

  Operating income as a % of revenue  

 

21.8

%

 

 

19.4

%

 

 

20.6

%

 

 

18.8

%

  Add back:                
  Amortization related to acquisitions  

 

20,849

 

 

 

21,176

 

 

 

43,214

 

 

 

43,824

 

  Severance  

 

387

 

 

 

928

 

 

 

461

 

 

 

1,340

 

  Acquisition related adjustments (2)  

 

(2,591

)

 

 

404

 

 

 

(5,514

)

 

 

5,674

 

  Site consolidation costs, impairments and other items (3)  

 

2,287

 

 

 

146

 

 

 

2,356

 

 

 

293

 

  Total non-GAAP adjustments to operating income  

$

20,932

 

 

$

22,654

 

 

$

40,517

 

 

$

51,131

 

  Operating income, excluding non-GAAP adjustments  

$

149,725

 

 

$

127,168

 

 

$

274,296

 

 

$

246,594

 

  Non-GAAP operating income as a % of revenue  

 

25.3

%

 

 

23.5

%

 

 

24.1

%

 

 

23.7

%

                   
  Depreciation and amortization  

$

44,626

 

 

$

43,588

 

 

$

91,415

 

 

$

88,196

 

  Capital expenditures  

$

41,578

 

 

$

20,473

 

 

$

90,508

 

 

$

37,513

 

                   
Manufacturing Solutions                
  Revenue  

$

194,804

 

 

$

197,819

 

 

$

387,932

 

 

$

344,297

 

  Operating income  

 

62,503

 

 

 

56,717

 

 

 

108,871

 

 

 

106,154

 

  Operating income as a % of revenue  

 

32.1

%

 

 

28.7

%

 

 

28.1

%

 

 

30.8

%

  Add back:                
  Amortization related to acquisitions  

 

11,373

 

 

 

7,812

 

 

 

23,271

 

 

 

10,026

 

  Severance  

 

271

 

 

 

535

 

 

 

378

 

 

 

829

 

  Acquisition related adjustments (2)  

 

(18,888

)

 

 

686

 

 

 

(14,746

)

 

 

728

 

  Site consolidation costs, impairments and other items (3)  

 

519

 

 

 

-

 

 

 

1,940

 

 

 

40

 

  Total non-GAAP adjustments to operating income  

$

(6,725

)

 

$

9,033

 

 

$

10,843

 

 

$

11,623

 

  Operating income, excluding non-GAAP adjustments  

$

55,778

 

 

$

65,750

 

 

$

119,714

 

 

$

117,777

 

  Non-GAAP operating income as a % of revenue  

 

28.6

%

 

 

33.2

%

 

 

30.9

%

 

 

34.2

%

                   
  Depreciation and amortization  

$

18,000

 

 

$

13,952

 

 

$

36,482

 

 

$

20,521

 

  Capital expenditures  

$

24,431

 

 

$

13,602

 

 

$

47,259

 

 

$

20,712

 

                   
Unallocated Corporate Overhead  

$

(43,411

)

 

$

(66,261

)

 

$

(93,869

)

 

$

(127,879

)

  Add back:                
  Severance  

 

167

 

 

 

-

 

 

 

1,254

 

 

 

(151

)

  Acquisition related adjustments (2)  

 

3,014

 

 

 

15,064

 

 

 

7,130

 

 

 

25,624

 

  Total non-GAAP adjustments to operating expense  

$

3,181

 

 

$

15,064

 

 

$

8,384

 

 

$

25,473

 

  Unallocated corporate overhead, excluding non-GAAP adjustments  

$

(40,230

)

 

$

(51,197

)

 

$

(85,485

)

 

$

(102,406

)

                   
Total                
  Revenue  

$

973,131

 

 

$

914,607

 

 

$

1,887,060

 

 

$

1,739,173

 

  Operating income  

 

187,411

 

 

 

137,550

 

 

 

336,189

 

 

 

261,253

 

  Operating income as a % of revenue  

 

19.3

%

 

 

15.0

%

 

 

17.8

%

 

 

15.0

%

  Add back:                
  Amortization related to acquisitions  

 

37,694

 

 

 

34,334

 

 

 

75,795

 

 

 

64,535

 

  Severance  

 

1,278

 

 

 

1,463

 

 

 

3,220

 

 

 

2,025

 

  Acquisition related adjustments (2)  

 

(17,494

)

 

 

16,674

 

 

 

(11,776

)

 

 

33,002

 

  Site consolidation costs, impairments and other items (3)  

 

2,806

 

 

 

146

 

 

 

4,296

 

 

 

333

 

  Total non-GAAP adjustments to operating income  

$

24,284

 

 

$

52,617

 

 

$

71,535

 

 

$

99,895

 

  Operating income, excluding non-GAAP adjustments  

$

211,695

 

 

$

190,167

 

 

$

407,724

 

 

$

361,148

 

  Non-GAAP operating income as a % of revenue  

 

21.8

%

 

 

20.8

%

 

 

21.6

%

 

 

20.8

%

                   
  Depreciation and amortization  

$

76,421

 

 

$

68,105

 

 

$

151,720

 

 

$

129,613

 

  Capital expenditures  

$

82,852

 

 

$

46,431

 

 

$

163,316

 

 

$

74,461

 

(1)

  Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)

  These adjustments are related to the evaluation and integration of acquisitions, which primarily include transaction, third-party integration, and certain compensation costs, fair value adjustments associated with contingent consideration, and an adjustment related to certain indirect tax liabilities.

(3)

  Other items include certain third-party legal costs related to (a) an environmental litigation related to the Microbial business and (b) responses to a U.S. government industry-wide supply chain management inquiry applicable to our Safety Assessment business.
     
 
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
 
 
SCHEDULE 5
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)(1)
(in thousands, except per share data)
                 
    Three Months Ended   Six Months Ended
    June 25, 2022   June 26, 2021   June 25, 2022   June 26, 2021
                 
Net income attributable to common shareholders  

$

109,321

 

 

$

88,448

 

 

$

202,343

 

 

$

149,978

 

Add back:                
Non-GAAP adjustments to operating income (Refer to previous schedule)  

 

24,284

 

 

 

52,617

 

 

 

71,535

 

 

 

99,895

 

Write-off of deferred financing costs and fees related to debt financing  

 

-

 

 

 

110

 

 

 

-

 

 

 

26,089

 

Venture capital and strategic equity investment losses (gains), net  

 

9,612

 

 

 

(9,809

)

 

 

23,515

 

 

 

6,910

 

Other (2)  

 

3,608

 

 

 

(572

)

 

 

3,965

 

 

 

(2,942

)

Tax effect of non-GAAP adjustments:                
Non-cash tax provision related to international financing structure (3)  

 

1,341

 

 

 

1,285

 

 

 

2,463

 

 

 

2,320

 

Enacted tax law changes  

 

-

 

 

 

10,036

 

 

 

-

 

 

 

10,036

 

Tax effect of the remaining non-GAAP adjustments  

 

(6,293

)

 

 

(8,316

)

 

 

(20,813

)

 

 

(29,329

)

Net income attributable to common shareholders, excluding non-GAAP adjustments  

$

141,873

 

 

$

133,799

 

 

$

283,008

 

 

$

262,957

 

                 
Weighted average shares outstanding - Basic  

 

50,823

 

 

 

50,297

 

 

 

50,732

 

 

 

50,138

 

Effect of dilutive securities:                
Stock options, restricted stock units and performance share units  

 

460

 

 

 

1,037

 

 

 

561

 

 

 

1,087

 

Weighted average shares outstanding - Diluted  

 

51,283

 

 

 

51,334

 

 

 

51,293

 

 

 

51,225

 

                 
Earnings per share attributable to common shareholders:                
Basic  

$

2.15

 

 

$

1.76

 

 

$

3.99

 

 

$

2.99

 

Diluted  

$

2.13

 

 

$

1.72

 

 

$

3.94

 

 

$

2.93

 

                 
Basic, excluding non-GAAP adjustments  

$

2.79

 

 

$

2.66

 

 

$

5.58

 

 

$

5.24

 

Diluted, excluding non-GAAP adjustments  

$

2.77

 

 

$

2.61

 

 

$

5.52

 

 

$

5.13

 

(1)

  Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)

  Adjustments included in 2022 relate to a purchase price adjustment in connection with the 2021 divestiture of RMS Japan and a reversal of an indemnification asset related to a prior acquisition. Adjustments included in 2021 include gains on an immaterial divestiture and the finalization of an annuity purchase related to the termination of the Company's U.S. pension plan.

(3)

  This adjustment relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure.
     
 
 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                 
SCHEDULE 6
RECONCILIATION OF GAAP REVENUE GROWTH
TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1)
                 
                 
Three Months Ended June 25, 2022   Total CRL   RMS Segment   DSA Segment   MS Segment
                 
Revenue growth, reported  

6.4 %

 

5.5 %

 

9.6 %

 

(1.5)%

Decrease due to foreign exchange  

3.4 %

 

3.0 %

 

3.3 %

 

4.1 %

Contribution from acquisitions (2)  

(2.3)%

 

(7.2)%

 

- %

 

(4.0)%

Impact of divestitures (3)  

2.0 %

 

7.2 %

 

- %

 

2.4 %

Non-GAAP revenue growth, organic (4)  

9.5 %

 

8.5 %

 

12.9 %

 

1.0 %

                 
Six Months Ended June 25, 2022   Total CRL   RMS Segment   DSA Segment   MS Segment
                 
Revenue growth, reported  

8.5 %

 

2.6 %

 

9.1 %

 

12.7 %

Decrease due to foreign exchange  

2.6 %

 

2.1 %

 

2.5 %

 

3.5 %

Contribution from acquisitions (2)  

(3.4)%

 

(3.6)%

 

(0.3)%

 

(12.7)%

Impact of divestitures (3)  

1.8 %

 

7.5 %

 

(0.1)%

 

1.4 %

Non-GAAP revenue growth, organic (4)  

9.5 %

 

8.6 %

 

11.2 %

 

4.9 %

(1)

  Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)

  The contribution from acquisitions reflects only completed acquisitions.

(3)

  The Company sold both its RMS Japan operations and its gene therapy CDMO site in Sweden on October 12, 2021. This adjustment represents the revenue from these businesses for all applicable periods in 2021.

(4)

  Organic revenue growth is defined as reported revenue growth adjusted for acquisitions, divestitures and foreign exchange.

 

Investor Contacts:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com

Media Contact:
Amy Cianciaruso
Corporate Vice President,
Public Relations
781.222.6168
amy.cianciaruso@crl.com

Source: Charles River Laboratories International, Inc.

Featured Report

2021 Annual Report (PDF)

Charles River Corporate Citizenship Report
View PDF
Print PDF